GH — Guardant Health, Inc. stock price, charts and financials

QT67Guardant Health, Inc.

Guardant Health, Inc. (NASDAQ: GH) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
169.24
+0.76+0.45%
OverviewShort InterestFilings
GHQT67Guardant Health, Inc.·NASDAQ
169.24+0.45%
TA
Loading chart...
Signal & projected range
Insider selling clusterHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
LH-0.19%$318.55DGX-0.47%$237.23ILMN+1.52%$190.82MTD+0.52%$1436.82WAT+0.86%$410.35MEDP+1.11%$597.21IQV+1.21%$241.58RVTY+0.96%$115.77
Snapshot
Index-P/E-EPS (ttm)-3.49Insider Own3.71%Shs Outstand134.20MPerf Week4.01%
Market Cap22.61BForward P/E-EPS next Y-1.96Insider Trans-15.89%Shs Float128.82MPerf Month2.68%
Enterprise Value23.25BPEG10.94EPS next Q-0.28Inst Own-Short Float8.87%Perf Quarter82.61%
Income-461.23MP/S19.11EPS this Y11.25%Inst Trans-Short Ratio4.32Perf Half Y71.29%
Sales1.18BP/B-EPS next Y36.73%ROA-23.71%Short Interest11.42MPerf YTD64.95%
Book/sh-P/C-EPS next 5Y-ROE211.46%52W High177.39 -4.59%Perf Year277.84%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-29.30%52W Low48.47 249.18%Perf 3Y343.43%
Dividend Est.-EV/EBITDA-Sales past 3/5Y29.71% 27.89%Gross Margin65.01%Volatility4.43% 4.85%Perf 5Y52.96%
Dividend TTM-EV/Sales19.65EPS Y/Y TTM1.97%Oper. Margin-39.75%ATR (14)8.54Perf 10Y-
Dividend Ex-Date-Quick Ratio3.71Sales Y/Y TTM60.08%Profit Margin-38.33%RSI (14)63.30Recom2.06
Dividend Gr. 3/5Y-Current Ratio4.03EPS Q/Q-104.55%SMA208.83%Beta1.59Target Price184.50
Payout0.00%Debt/Eq-Sales Q/Q44.40%SMA5015.18%Rel Volume0.80Prev Close168.48
Employees2,506LT Debt/Eq-16.99EarningsOct 28SMA20053.58%Avg Volume2.70MPrice169.24
IPO DateOct 04, 2018Option/ShortYes / YesEPS/Sales Surpr.-18.14% 6.60%Net Debt/EBITDA-1.57Volume2,159,895Change0.45%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-04-26ReiteratedMorgan StanleyOverweight$175 → $185
Aug-04-26ReiteratedStephensOverweight$170 → $195
Aug-04-26ReiteratedPiper SandlerOverweight$135 → $193
Jul-31-26ReiteratedRBC CapitalOutperform$185 → $210
Jul-31-26ReiteratedStifel Nicolaus$130 → $180
Jul-31-26ReiteratedGoldman SachsBuy$185 → $210
Jul-31-26ReiteratedBTIGBuy$190 → $195
Jul-31-26ReiteratedBarclaysOverweight$115 → $200
Jul-31-26ReiteratedMizuhoOutperform$175 → $200
Jul-16-26ReiteratedGuggenheimBuy$160 → $190
Latest News
Aug-06-26
Aug-06-2605:38PM
A Look at Guardant Health Inc (GH) After 3.4% Decline -- GF Value $64.71 vs Price $157.58gurufocus.com
08:13AM
Alger Small Cap Focus Fund Q2 2026 Portfolio ReviewSeekingAlpha
Aug-01-26
Aug-01-2611:22AM
GE Aerospace, AI Play Lead Five Stocks Near Buy Pointsinvestors.com
Jul-31-26
Jul-31-2607:00AM
AngloGold Ashanti Q2 30 June 2026 Earnings Release and Dividend Declarationgurufocus.com
Jul-30-26
Jul-30-2611:23PM
Guardant Health (NASDAQ:GH) Shares Surge After Q2 Revenue Beat and Raised 2026 OutlookChartMill
09:33PM
Guardant Health, Inc. (GH) Q2 2026 Earnings Call Transcriptseekingalpha.com
08:31PM
Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimateszacks.com
07:31PM
Guardant Health (GH) Q2 Earnings: How Key Metrics Compare to Wall Street Estimateszacks.com
04:05PM
Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidancebusinesswire.com
Jul-29-26
Jul-29-2604:05PM
Guardant Health to Participate in Upcoming Investor Conferencesbusinesswire.com
10:16AM
Wall Street's Insights Into Key Metrics Ahead of Guardant Health (GH) Q2 Earningszacks.com
Jul-28-26
Jul-28-2607:13AM
Actor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who Have Lost Their Lives to Colorectal Cancerbusinesswire.com
Jul-27-26
Jul-27-2603:54AM
Caxton Associates LLP Invests $831,000 in Guardant Health, Inc. $GHdefenseworld.net
Jul-24-26
Jul-24-2606:53AM
ISCG vs. VOOG: Small-Cap Growth vs. S&P 500 Growth -- Which ETF Is the Better Buy?fool.com
Jul-23-26
Jul-23-2611:06AM
Guardant Health (GH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Releasezacks.com
Company

Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,183982739——————
Cost of Goods Sold Incl. D&A414349290——————
Gross Profit770633449——————
Selling, General and Administrative Excl. Other864706545——————
Research and Development376364348——————
Other Operating Expense
000——————
Operating Income-470-437-444——————
Interest Expense443——————
Unusual Expense
—————————
Non-Operating Income (Expense)212411——————
Net Income Before Taxes-455-418-435——————
Income Taxes-2-11——————
Consolidated Net Income-453-416-436——————
Net Income From Continuing Operations-453-416-436——————
Net Income-453-416-436——————
EPS (Recurring)-3.49-3.32-3.56——————
EPS (Basic, Before Extraordinaries)-3.49-3.32-3.56——————
EPS (Diluted)-3.49-3.32-3.56——————
EBITDA-411-374-390——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio18.8813.005.08——————
Gross Margin65.0964.4660.76——————
Operating Margin-39.73-44.50-60.08——————
Net Margin-38.29-42.36-59.00——————
Shares Outstanding132125123——————
Market Capitalization22,34012,7683,758——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$190.60$147.63$104.66$61.69$18.72● Close Price0.00M14.11M28.22M42.32M56.43MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Hidalgo Medina ManuelDirectorAug 05 '26Option Exercise32.5595030,9226,256Aug 06
Hidalgo Medina ManuelDirectorAug 05 '26Sale164.241,700279,2024,556Aug 06
CLARK IAN TDirectorAug 04 '26Sale158.9214,1802,253,4512,975Aug 05
CLARK IAN TDirectorAug 04 '26Option Exercise60.639,088550,99817,155Aug 05
MIGNONE ROBERTODirectorJul 21 '26Option Exercise0.0026409,746Jul 22
Hidalgo Medina ManuelDirectorJul 17 '26Option Exercise0.0023205,306Jul 20
Tariq MusaDirectorJul 16 '26Sale163.2911618,94211,182Jul 16
Tariq MusaDirectorJul 15 '26Option Exercise0.00250011,298Jul 16
Kalia KumudChief Information OfficerJul 01 '26Option Exercise0.006,046046,860Jul 02
Freeman ChrisChief Commercial OfficerJul 01 '26Option Exercise0.007,414068,515Jul 02
Chudova DaryaChief Technology OfficerJul 01 '26Option Exercise0.008,030082,691Jul 02
Bell Michael BrianChief Financial OfficerJul 01 '26Option Exercise0.007,278055,730Jul 02
Eltoukhy HelmyCo-Chief Executive OfficerJul 01 '26Option Exercise0.0033,71202,048,020Jul 02
Saia John G.Chief Legal OfficerJul 01 '26Option Exercise0.007,063043,498Jul 02
Monroe Terilyn J.Chief People OfficerJul 01 '26Option Exercise0.004,020025,078Jul 02
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.